KalVista Pharmaceuticals, Inc.
KALV
$19.56
-$1.30-6.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 337.66% | 860.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 337.66% | 860.17% | |||
| Cost of Revenue | -7.46% | -16.04% | |||
| Gross Profit | 10,111.13% | 103.26% | |||
| SG&A Expenses | 29.85% | 4.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.59% | -1.15% | |||
| Operating Income | 72.39% | 21.96% | |||
| Income Before Tax | 73.65% | 18.32% | |||
| Income Tax Expenses | -429.09% | 0.00% | |||
| Earnings from Continuing Operations | 89.14% | 17.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 89.14% | 17.66% | |||
| EBIT | 72.39% | 21.96% | |||
| EBITDA | 73.49% | 22.12% | |||
| EPS Basic | 89.40% | 18.26% | |||
| Normalized Basic EPS | 75.71% | 18.41% | |||
| EPS Diluted | 89.40% | 18.26% | |||
| Normalized Diluted EPS | 75.71% | 18.41% | |||
| Average Basic Shares Outstanding | 2.42% | 0.72% | |||
| Average Diluted Shares Outstanding | 2.42% | 0.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||